Pharsight

Verzenio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7855211 ELI LILLY AND CO Protein kinase inhibitors
Dec, 2029

(6 years from now)

Verzenio is owned by Eli Lilly And Co.

Verzenio contains Abemaciclib.

Verzenio has a total of 1 drug patent out of which 0 drug patents have expired.

Verzenio was authorised for market use on 28 September, 2017.

Verzenio is available in tablet;oral dosage forms.

Verzenio can be used as in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; in combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; in combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer.

The generics of Verzenio are possible to be released after 15 December, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Oct 12, 2024
New Indication (I) Oct 12, 2024

Drugs and Companies using ABEMACICLIB ingredient

Market Authorisation Date: 28 September, 2017

Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (h...

Dosage: TABLET;ORAL

More Information on Dosage

VERZENIO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic